Victor Lim
Biography
Overview
Victor Lim is an associate in the Mergers & Acquisitions and Private Equity Practice, based in Singapore.
Victor advises on a wide range of corporate transactions, including domestic and cross-border mergers and acquisitions, joint ventures and corporate restructuring. His experience includes advising publicly listed companies, multinational corporations and private equity firms in a broad spectrum of industries, including the real estate, healthcare, infrastructure and fintech sectors.
Experience
Macquarie Digital Tower Pte. Limited and Phil-Tower Consortium, Inc. in the auction sale for the acquisition and leaseback of telecommunication infrastructure assets in Visayas and Mindanao, the Philippines, from Globe Consortium, Inc. and its subsidiaries.
Zip Co Limited (ASX: Z1P) in its strategic investment in ZestMoney, the largest and fastest-growing buy now, pay later (BNPL) platform in India.
VPC Impact Acquisition Holdings II (Nasdaq: VPCB) on its US$2.5 billion business combination with FinAccel, the parent of artificial intelligence-enabled Indonesian digital consumer credit platform Kredivo.
bKash on a Series C investment round with SoftBank Vision Fund II, the tech investment fund of SoftBank, investing US$400 million for a 20 percent stake through a primary and secondary investment.
Brenntag on its acquisition of the remaining 49 percent of Teehai Chem, a leading chemicals distribution company in Singapore. This transaction follows from the earlier 2019 acquisition by Brenntag of a 51 percent stake in Teehai Chem.
ABB on its separation of Accelleron (formerly ABB Turbocharging), a global leader in turbocharging technologies and optimization solutions with a presence in 50 countries, from the ABB group in preparation of its US$2.7 billion spin-off and listing on SIX Swiss Exchange.
A leading global financial sponsor on its co-investment with a sovereign wealth fund into The CrownX, the integrated consumer retail platform of Vietnamese conglomerate Masan Group.
A leading global financial sponsor on its investment into a group of companies in India in the business of researching, developing, manufacturing, marketing and commercialization of bio-pharmaceutical products, including vaccines for COVID-19.
